Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial

Casper Steenholdt, Jørn Brynskov, Ole Østergaard Thomsen, Lars Kristian Munck, Jan Fallingborg, Lisbet Ambrosius Christensen, Gitte Pedersen, Jens Christian William Kjeldsen, Bent Ascanius Jacobsen, Anne Sophie Oxholm, Jakob Kjellberg, Klaus Bendtzen, Mark Andrew Ainsworth

405 Citationer (Scopus)

Abstract

Although the reasons for secondary loss of response to infliximab (IFX) maintenance therapy in Crohn's disease vary, dose intensification is usually recommended. This study investigated the cost-effectiveness of interventions defined by an algorithm designed to identify specific reasons for therapeutic failure.
OriginalsprogEngelsk
TidsskriftGut
Vol/bind4
Udgave nummer63
Sider (fra-til)919
Antal sider9
ISSN0017-5749
DOI
StatusUdgivet - 2014

Fingeraftryk

Dyk ned i forskningsemnerne om 'Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial'. Sammen danner de et unikt fingeraftryk.

Citationsformater